MTOR hyperactivation in down syndrome hippocampus appears early during development

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 7, 2014, Pages 671-683

  Iyer, Anand M ^a   Van Scheppingen, Jackelien ^a   Milenkovic, Ivan ^d   Anink, Jasper J ^a   Adle Biassette, Homa ^e   Kovacs, Gabor G ^d   Aronica, Eleonora ^a,b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Alzheimer disease; Development; Down syndrome; Hippocampus; Mammalian target of rapamycin

Indexed keywords

DNA BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; SYNAPTOPHYSIN; TAU PROTEIN; VIMENTIN;

ADOLESCENT; ALZHEIMER DISEASE; ARTICLE; BRAIN DEVELOPMENT; CELLULAR DISTRIBUTION; CHILD; CONTROLLED STUDY; DOWN SYNDROME; ENZYME ACTIVATION; FEMALE; FETUS; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEWBORN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; ALZHEIMER DISEASE; BIOTRANSFORMATION; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; NEURONS; PARAFFIN EMBEDDING; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TISSUE FIXATION; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84903313046     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000083     Document Type: Article

References (53)

1. Schaefers AT, Teuchert-Noodt G. Developmental neuroplasticity and the origin of neurodegenerative diseases [published online ahead of print May 24, 2013]. World J Biol Psychiatry. doi: 10.3109/15622975. 2013.797104.
2. Mehler MF, Gokhan S. Developmental mechanisms in the pathogenesis of neurodegenerative diseases. Prog Neurobiol 2001;63:337-63
3. Ben-Ari Y. Neuro-archaeology: Pre-symptomatic architecture and signature of neurological disorders. Trends Neurosci 2008;31:626-36
4. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011;23:744-55
5. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93
6. Wong M. Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J 2013;36:40-50
7. Crino PB. mTOR: A pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 2011;17:734-42
8. Troca-Marin JA, Alves-Sampaio A, Montesinos ML. Deregulated mTORmediated translation in intellectual disability. Prog Neurobiol 2012;96: 268-82
9. Cai Z, Zhao B, Li K, et al. Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for Alzheimer's disease? J Neurosci Res 2012;90:1105-18
10. Caccamo A, Majumder S, Richardson A, et al. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J Biol Chem 2010;285:13107-20
11. Ma T, Hoeffer CA, Capetillo-Zarate E, et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One 2010;5:e12845. doi: 10.1371/journal.pone. 0012845.
12. Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010;5:e9979. doi: 10.1371/journal.pone. 0009979.
13. Li X, Alafuzoff I, Soininen H, et al. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J 2005;272:4211-20
14. Cork LC. Neuropathology of Down syndrome and Alzheimer disease. Am J Med Genet Suppl 1990;7:282-86
15. Contestabile A, Benfenati F, Gasparini L. Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome. Prog Neurobiol 2010;91:1-22
16. Garner CC, Wetmore DZ. Synaptic pathology of Down syndrome. Adv Exp Med Biol 2012;970:451-68
17. Talos DM, Sun H, Zhou X, et al. The interaction between early life epilepsy and autistic-like behavioral consequences: A role for the mammalian target of rapamycin (mTOR) pathway. PLoS One 2012;7:e35885
18. Thal DR, Del Tredici K, Ludolph AC, et al. Stages of granulovacuolar degeneration: Their relation to Alzheimer's disease and chronic stress response. Acta Neuropathol 2011;122:577-89
19. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer diseaseY associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404
20. Ravizza T, Boer K, Redeker S, et al. The IL-1beta system in epilepsyassociated malformations of cortical development. Neurobiol Dis 2006;24: 128-43
21. Iyer A, Zurolo E, Spliet WGM, et al. Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia 2010;51(9):1763-73
22. Aronica E, Gorter JA, Redeker S, et al. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy. Neuropathol Appl Neurobiol 2005;31: 280-91
23. Anjum R, Blenis J. The RSK family of kinases: Emerging roles in cellular signaling. Nat Rev Mol Cell Biol 2008;9:747-58
24. Boer K, Encha-Razavi F, Sinico M, et al. Differential distribution of group I metabotropic glutamate receptors in developing human cortex. Brain Res 2010;1324:24-33
25. Yang P, Zhang J, Zhao L, et al. Developmental distribution pattern of metabotropic glutamate receptor 5 in prenatal human hippocampus. Neurosci Bull 2012;28:704-14
26. Catania MV, D'Antoni S, Bonaccorso CM, et al. Group I metabotropic glutamate receptors: A role in neurodevelopmental disorders? Mol Neurobiol 2007;35:298-307
27. Hou L, Klann E. Activation of the phosphoinositide 3-kinaseYAktYmammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptorYdependent long-term depression. J Neurosci 2004;24: 6352-61
28. Banko JL, Hou L, Poulin F, et al. Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptorYdependent long-term depression. J Neurosci 2006;26: 2167-73
29. Page G, Khidir FA, Pain S, et al. Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signalYregulated kinase (ERK 1/2) signaling pathways in rat striatal and hippocampal synaptoneurosomes. Neurochem Int 2006;49:413-21
30. Sharma A, Hoeffer CA, Takayasu Y, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010;30:694-702
31. Bhakar AL, Dolen G, Bear MF. The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 2012;35:417-43
32. Schiering IAM, De Haan TR, Niermeijer JMF, et al. Correlation between clinical and histological findings in the human neonatal hippocampus following perinatal asphyxia. J Neuropathol Exp Neurol 2014;73:324-34
33. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene 2006;25:6373-83
34. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004;18:2893-904
35. Marin-Padilla M. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. J Comp Neurol 1976;167: 63-81
36. Mann DM. The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev 1988;43:99-136
37. de la Monte SM, Hedley-Whyte ET. Small cerebral hemispheres in adults with Down's syndrome: Contributions of developmental arrest and lesions of Alzheimer's disease. J Neuropathol Exp Neurol 1990;49:509-20
38. Sadowski M, Wisniewski HM, Tarnawski M, et al. Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology. Acta Neuropathol 1999;97:156-64
39. Yonezawa K, Yoshino KI, Tokunaga C, et al. Kinase activities associated with mTOR. Curr Top Microbiol Immunol 2004;279:271-82
40. Holmes GL, Stafstrom CE, Tuberous Sclerosis Study Group. Tuberous sclerosis complex and epilepsy: Recent developments and future challenges. Epilepsia 2007;48:617-30
41. Pullen N, Thomas G. The modular phosphorylation and activation of p70S6K. FEBS Lett 1997;410:78-82
42. Rosner M, Siegel N, Valli A, et al. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids 2010;38:223-28
43. Manning BD. Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004;167:399-403
44. Dello Russo C, Lisi L, Feinstein DL, et al. mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis. Glia 2013;61:301-11
45. Sosunov AA, Wu X, McGovern RA, et al. The mTOR pathway is activated in glial cells in mesial temporal sclerosis. Epilepsia 2012; 53(Suppl 1):78-86
46. Oka A, Takashima S. The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains. Acta Neuropathol 1999;97:275-78
47. Liu Y, Su Y, Wang J, et al. Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochem Int 2013;62:458-67
48. Sarnat HB, Flores-Sarnat L, Crino P, et al. Hemimegalencephaly: Foetal tauopathy with mTOR hyperactivation and neuronal lipidosis. Folia Neuropathol 2012;50:330-45
49. Iyer A, Prabowo A, Anink J, et al. Cell injury and premature neurodegeneration in focal malformations of cortical development. Brain Pathol 2014;24:1-17
50. Castellani RJ, Gupta Y, Sheng B, et al. A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: Parallels to stress granules. Lab Invest 2011;91:1777-86
51. Ball MJ, Lo P. Granulovacuolar degeneration in the ageing brain and in dementia. J Neuropathol Exp Neurol 1977;36:474-87
52. Funk KE, Mrak RE, Kuret J. Granulovacuolar degeneration (GVD) bodies of Alzheimer's disease (AD) resemble late-stage autophagic organelles. Neuropathol Appl Neurobiol 2011;37:295-306
53. Ball MJ, Nuttall K. Neurofibrillary tangles, granulovacuolar degeneration, and neuron loss in Down syndrome: Quantitative comparison with Alzheimer dementia. Ann Neurol 1980;7:462-65